In this study, we selected RNF180 and SFRP2 genes from GC patients, patients with precancerous gastric lesions, and healthy individuals, and compared and co-analyzed them with conventional tumor markers (CEA, CA199, and CA125). This evidence concerns the gene RNF180 and neoplasm.